Real-World study tests Once-Daily pill for ulcerative colitis in chinese adults

NCT ID NCT07705126

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study looks at how the oral medication etrasimod works for Chinese adults with active ulcerative colitis (UC) in real-world settings. About 500 participants will take etrasimod as part of their routine care and be followed for at least 52 weeks. Researchers will track changes in UC symptoms, disease flares, treatment adjustments, and safety. The goal is to understand how etrasimod performs outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
etrasimod, an oral medication taken once daily that reduces gut inflammation
What this could lead to
If successful, this study could show that etrasimod is effective and safe for Chinese adults with active ulcerative colitis in everyday clinical practice, potentially expanding treatment options.
What could go wrong
This is an observational registry, not a controlled trial, so results may be influenced by patient differences and real-world variability. It also focuses only on Chinese adults, so findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tangdu Hospital

    Xi’an, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.